Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow XBiotech Inc.

Get SEC filing alerts via email and in your feed for XBiotech Inc.

XBIT

XBiotech Inc.

About XBiotech Inc.

XBiotech Inc. is a biopharmaceutical company specializing in discovering and developing True Human monoclonal antibodies from naturally immune donors. Its focus includes therapies targeting inflammatory and infectious diseases, notably IL-1a inhibitors for conditions like cancer, arthritis, and stroke. The company leverages proprietary manufacturing and clinical infrastructure, aiming to deliver safer, more effective biologics with potential for targeted, differentiated treatments across multiple medical indications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from XBiotech Inc.

1
1
XBiotech Inc. XBiotech Reports $5.5 Million Net Loss in Q1 2026, Improved from $10.9 Million Loss in Q1 2025

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
XBiotech Inc. XBiotech Reports $45.5 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
XBiotech Inc. XBiotech Reports $6 Million Net Loss in Q3 2025, Cash Reserves Decline

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
XBiotech Inc. XBiotech Reports $1.8 Million Net Loss for Q2 2025, Down from $13 Million Last Year

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
XBiotech Inc. XBiotech Reports $10.9 Million Net Loss in Q1 2025, Cash Reserves Decrease

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
XBiotech Inc. XBiotech Reports $38.5 Million Net Loss for Fiscal Year Ending December 31, 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
XBiotech Inc. XBiotech Reports Mixed Q3 Results, Decrease in Cash and Cash Equivalents

Via official filing (AI summary) | over 1 year ago | 0 comments